Skip to main content

Table 2 Association between the reason for discontinuation of the first TNFi and response to the second TNFi over time

From: Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?

Reason to discontinue the first TNFi*

Outcome for the second TNFi OR (95% CI)

ASDAS-CII (n = 135)

ASDAS-MII (n = 135)

ASDAS-LDA (n = 166)

ASDAS-ID (n = 166)

BASDAI50 (n = 147)

(Ref. primary failure)

 -Secondary failure

1.9 (0.7; 4.8)

4.8 (1.3; 18.2)

1.2 (0.6; 2.4)

7.3 (1.9; 27.7)

1.4 (0.6; 3.0)

 -Adverse events

1.5 (0.6; 3.5)

2.4 (0.6; 9.6)

0.9 (0.5; 1.7)

9.1 (2.5; 33.3)

1.1 (0.5; 2.3)

 -Others

1.0 (0.3; 3.8)

1.7 (0.1; 19.4)

1.0 (0.4; 2.4)

7.7 (1.6; 37.9)

0.5 (0.1; 1.7)

  1. ASDAS Ankylosing Spondylitis Disease Activity Score, LDA low disease activity, ID inactive disease, CII clinically important improvement, MII major important improvement, BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50, N number
  2. *Generalized estimated equation (GEE) models with the reason for discontinuation of the first tumor necrosis factor inhibitor (TNFi) as a predictor (reference category: primary failure); all models adjusted for age, gender, and C-reactive protein. Models include all visits during follow-up of up to 10 years. Odds ratios (OR) in bold are statistically significant (p < 0.05)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us